DiaGenic and GE Healthcare agreed to use the former's gene expression profiling tools to develop a blood-based test for the early diagnosis of mild cognitive impairment, which has been linked to an increased risk of Alzheimer's disease. DiaGenic's technology will be used with GE's PET experimental imaging agent 18F-flutemetamol to detect a gene expression signature. The goal is to discover a biomarker that can be used to identify patients prone to Alzheimer's.

Related Summaries